MARVELD1 Antikörper (N-Term)

Produktnummer ABIN500236

Produktdetails anti-MARVELD1 Antikörper

Target: MARVELD1 (MARVEL Domain Containing 1 (MARVELD1))

Bindungsspezifität: N-Term

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser MARVELD1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Kreuzreaktivität (Details): Species reactivity (tested):Human, mouse, rat

Aufreinigung: Peptide affinity chromatography

Immunogen: MARVELD1 antibody was raised against a 16 amino acid peptide from near the amino terminus of human MARVELD1.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA. Western blot.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: PBS containing 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Store the antibody (in aliquots) at -20 °C.

Details zu MARVELD1

Target: MARVELD1 (MARVEL Domain Containing 1 (MARVELD1))

Andere Bezeichnung: MARVELD1 (MARVELD1 Produkte)

Synonyme: Mrvldc1 antikoerper, AI504298 antikoerper, GB14 antikoerper, MARVD1 antikoerper, MRVLDC1 antikoerper, RP11-548K23.8 antikoerper, bA548K23.8 antikoerper, MARVEL domain containing 1 antikoerper, MARVEL (membrane-associating) domain containing 1 antikoerper, Marveld1 antikoerper, MARVELD1 antikoerper

Hintergrund: MARVELD1, (MARVEL domain-containing 1), is one of the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain-containing proteins. It is a nuclear-localized protein that is widely expressed in normal human tissues. While it has been reported to be overexpressed in colon cancer, MARVELD1 protein levels are generally lower in several primary tumors including ovary, breast, kidney, bladder and liver. This lower level of MARVELD1 expression in tumors is thought to be due to a higher methylation status of the MARVELD1 promoter as treatment of MDA-MB-361 with 5-aza-2'-deoxycytidine restores MARVELD1 expression (1,3), suggesting that loss of MARVELD1 expression may contribute to tumorgenicity.Synonyms: MARVEL domain-containing protein 1, MRVLDC1

Gen-ID: 83742

UniProt: Q9BSK0